Skip to content
Open access

AI Based Advanced Drug Delivery System

Jul 2026 · ITU Journal of Metallurgy and Materials Engineering · 0 citations · 13 references

TL;DR

AutoML mitigates issues by automating key stages of the ML pipeline data preprocessing, model selection, hyperparameter tuning, and evaluation thereby enhancing scalability and reducing dependence on domain expertise.

Abstract

The integration of Artificial Intelligence (AI) into pharmaceutical research has accelerated drug discovery by streamlining target identification, compound screening, and candidate optimization. Yet, developing effective AI-driven systems remains challenging due to high- dimensional data and the need for expert-driven model tuning. Automated Machine Learning (AutoML) mitigates these issues by automating key stages of the ML pipeline data preprocessing, model selection, hyperparameter tuning, and evaluation thereby enhancing scalability and reducing dependence on domain expertise. AutoML's ability to handle diverse datasets, from omics to lipid nanoparticle (LNP) optimization enabling faster translation of candidates into clinically viable therapeutics. Techniques such as transfer learning, graph neural networks, and transformer-based models enrich molecular representations and improve predictive performance. Advances like DNN-VS further bolster tasks such as virtual screening and bioactivity prediction. Nonetheless, challenges persist in achieving model interpretability and integrating multimodal data. Future efforts should focus on adaptive, domain-aware AutoML strategies to overcome these limitations.

Read PDF

Similar papers

Review Aug 2026

Advancing cancer drug discovery through the integration of machine learning and high-throughput screening.

This review highlights the synergy between AI and HTS, emphasizing DL techniques such as convolutional neural networks for bioactivity prediction, recurrent neural networks for de novo design, and reinforcement learning for property optimization.

K. Herbetko, Katarzyna Herbetko, Magdalena Mikołajek et al. · 0 citations
Review Jul 2026

Emerging Trends in Artificial Intelligence-Driven Drug Discovery: Balancing Chemical Design and Pharmacological Properties for Cancer Therapy.

This review emphasizes the influence of new AI platforms like AlphaFold3, molecular interactions are structurally optimized (MISATO), and ZairaChem on the discovery of oncology drugs and examines how AI reconciles chemical design with pharmacological feasibility.

Mohsin Ali, Muhammad Ali Tajwar, Farid Ahmed et al. · 0 citations
Review Open access 2025

AI-Assisted Drug Discovery: Emerging Technologies and Challenges

This study reviews AI-driven drug discovery methods, presents a structured AI pipeline from data collection to candidate selection, and evaluates performance using metrics such as prediction accuracy, screening efficiency, lead optimization success, and toxicity reduction.

Joseph Robin · 0 citations
Review Aug 2026

Artificial Intelligence for Drug Delivery.

Drug delivery, serving as a pivotal link between pharmaceutical innovation and clinical implementation, faces numerous challenges in achieving optimal therapeutic outcomes. With the advancement of computational methodologies and technological tools, artificial intelligence (AI) has been increasingly applied in pharmaceutical sciences, ranging from target discovery to product management. In recent years, AI has been extensively used in drug delivery to tailor formulation design, enhance therapeutic efficacy, and reduce side effects. However, limitations in data quality and model interpretability frequently restrict AI's predictive performance and hinder its clinical applicability. This overview highlights the applications of AI in drug delivery, focusing on AI-designed drug formulations, AI-driven prediction of ADMET properties, and AI-assisted drug delivery devices, which support the development of precision medicine. Additionally, the translation challenges and future perspectives in this field are discussed.

Xinmin Yu, Xinyun Jiang, Tao Sheng et al. · 0 citations
Review 2026

Artificial Intelligence in Drug Discovery: Translational Bottlenecks, Biomedical Engineering Constraints, and Commercial Realities

Artificial intelligence (AI) has emerged as a major technological development influencing modern pharmaceutical research and development. Machine learning, computational biology, and large-scale biological data analysis have the potential to improve target identification, molecular optimization, and clinical development. However, despite growing enthusiasm, significant uncertainty remains regarding the ability of AI systems to overcome the biological, regulatory, and translational challenges that have historically limited pharmaceutical innovation. This review examines AI-driven drug discovery from a biomedical engineering and translational perspective. It evaluates the scientific foundations of AIenabled pharmaceutical development, including target identification, molecular design, and multimodal biological modeling, while analyzing key barriers involving biological complexity, clinical translation, regulatory oversight, and commercialization. Case studies of Recursion Pharmaceuticals and Schrödinger demonstrate both the opportunities and limitations associated with integrating computational approaches into therapeutic development. The analysis suggests that AI will become an increasingly important component of pharmaceutical workflows; however, long-term impact will depend less on algorithmic advancement alone and more on effective integration with biological validation, experimental rigor, clinical evidence, and scalable translational infrastructure. AI should therefore be viewed as an enabling technology that enhances decision-making and prioritization rather than a replacement for traditional biomedical research processes.

Andrew Matelis · 0 citations